Research Study

A Study to Assess the Renoprotective Effects of the SGLT2 Inhibitor Dapagliflozin in Non-Diabetic Patients With Proteinuria: a Randomized Double Blind 6-Weeks Cross-Over Trial
Principal Investigator 
Sean Barbour

Overview

Body Locations and Systems 
Kidney Disease
ClinicalTrials.gov# 
NCT03190694
Status 
Recruiting
Study Start/End 
Mar 1, 2019 to Dec 31, 2021
Locations 
Diamond Health Care Centre, St. Paul's Hospital
Phone 
604-875-5950
Purpose of Study 

The purpose of this study is to determine whether dapagliflozin lowers proteinuria in patients with non-diabetic chronic kidney disease.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.